• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

    148.96 -5.88 (-3.80%)
    Streaming Delayed Price Updated: 11:34 AM EDT, Jun 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 142,711
    Open 154.15
    Bid (Size) 148.27 (100)
    Ask (Size) 149.65 (200)
    Prev. Close 154.84
    Today's Range 147.47 - 161.38
    52wk Range 21.55 - 155.00
    Shares Outstanding 98,935,025
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire

    Performance

    YTD
    +48.5%
    +48.5%
    1 Month
    +32.3%
    +32.3%
    3 Month
    +34.6%
    +34.6%
    6 Month
    +47.3%
    +47.3%
    1 Year
    +560.9%
    +560.9%

    More News

    Read More
    News headline image
    What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    Palvella Therapeutics (NASDAQ:PVLA) Reports Wider Q1 Loss but NDA Submission Stay on Track ↗
    Via Chartmill
    News headline image
    Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
    From Palvella Therapeutics Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Palvella Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Palvella Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Palvella Therapeutics, Inc. - Common Stock trade on?
    Palvella Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Palvella Therapeutics, Inc. - Common Stock?
    The ticker symbol for Palvella Therapeutics, Inc. - Common Stock is PVLA on the Nasdaq Stock Market
    What is the current price of Palvella Therapeutics, Inc. - Common Stock?
    The current price of Palvella Therapeutics, Inc. - Common Stock is 148.96
    When was Palvella Therapeutics, Inc. - Common Stock last traded?
    The last trade of Palvella Therapeutics, Inc. - Common Stock was at 06/30/26 11:34 AM ET
    What is the market capitalization of Palvella Therapeutics, Inc. - Common Stock?
    The market capitalization of Palvella Therapeutics, Inc. - Common Stock is 14.74B
    How many shares of Palvella Therapeutics, Inc. - Common Stock are outstanding?
    Palvella Therapeutics, Inc. - Common Stock has 15B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.